Fractyl Health reported six‑month data from the REMAIN‑1 randomized trial showing its Revita endoscopic procedure reduced post‑GLP‑1 weight regain by roughly 70% versus sham in patients who discontinued incretin therapy after substantial weight loss. The trial targeted the growing cohort of patients who lose weight on GLP‑1 receptor agonists but then face rapid regain after stopping treatment. If durable, the effect positions Revita as a potential adjunct or rescue procedure for sustained weight management, potentially influencing payer coverage discussions for interventional options in metabolic care. The data will inform larger trials and commercial strategy discussions as clinicians balance procedural and pharmacologic approaches in obesity management.